Palisade Asset Management LLC Has $330,000 Stake in Boston Scientific Corporation (NYSE:BSX)

Palisade Asset Management LLC maintained its position in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,900 shares of the medical equipment provider’s stock at the end of the second quarter. Palisade Asset Management LLC’s holdings in Boston Scientific Corporation were worth $330,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. Gulf International Bank UK Ltd boosted its position in shares of Boston Scientific Corporation by 1.3% in the first quarter. Gulf International Bank UK Ltd now owns 415,615 shares of the medical equipment provider’s stock worth $10,336,000 after buying an additional 5,400 shares during the last quarter. Quadrant Capital Group LLC boosted its position in shares of Boston Scientific Corporation by 10.3% in the first quarter. Quadrant Capital Group LLC now owns 5,201 shares of the medical equipment provider’s stock worth $122,000 after buying an additional 487 shares during the last quarter. National Pension Service boosted its position in shares of Boston Scientific Corporation by 0.6% in the first quarter. National Pension Service now owns 1,058,667 shares of the medical equipment provider’s stock worth $25,884,000 after buying an additional 6,634 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Boston Scientific Corporation by 2.3% in the first quarter. Bank of Montreal Can now owns 511,136 shares of the medical equipment provider’s stock worth $12,711,000 after buying an additional 11,611 shares during the last quarter. Finally, Private Wealth Partners LLC boosted its position in shares of Boston Scientific Corporation by 3.4% in the first quarter. Private Wealth Partners LLC now owns 207,266 shares of the medical equipment provider’s stock worth $5,155,000 after buying an additional 6,796 shares during the last quarter. 92.08% of the stock is owned by institutional investors and hedge funds.

Shares of Boston Scientific Corporation (BSX) opened at 26.57 on Thursday. The company’s 50-day moving average is $27.43 and its 200-day moving average is $26.02. Boston Scientific Corporation has a one year low of $19.67 and a one year high of $28.51. The company has a market cap of $36.41 billion, a price-to-earnings ratio of 47.53 and a beta of 1.09.

Boston Scientific Corporation (NYSE:BSX) last announced its earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.01. The company had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. Boston Scientific Corporation’s revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.27 earnings per share. On average, equities analysts predict that Boston Scientific Corporation will post $1.26 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Palisade Asset Management LLC Has $330,000 Stake in Boston Scientific Corporation (NYSE:BSX)” was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/2796335/palisade-asset-management-llc-has-330000-stake-in-boston-scientific-corporation-nysebsx.html.

BSX has been the subject of a number of recent research reports. Guggenheim reissued a “buy” rating on shares of Boston Scientific Corporation in a research note on Wednesday, April 12th. Zacks Investment Research raised shares of Boston Scientific Corporation from a “sell” rating to a “hold” rating in a research note on Monday, April 24th. TheStreet raised shares of Boston Scientific Corporation from a “c+” rating to a “b” rating in a research note on Tuesday, April 25th. Needham & Company LLC reissued a “buy” rating and issued a $30.00 price objective (up from $29.00) on shares of Boston Scientific Corporation in a research note on Thursday, April 27th. Finally, Oppenheimer Holdings, Inc. set a $27.00 price target on shares of Boston Scientific Corporation and gave the stock a “hold” rating in a research note on Friday, April 28th. One analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $30.06.

In other news, EVP Kevin J. Ballinger sold 28,864 shares of the firm’s stock in a transaction that occurred on Wednesday, May 17th. The shares were sold at an average price of $26.14, for a total value of $754,504.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Daniel J. Brennan sold 92,158 shares of the firm’s stock in a transaction that occurred on Tuesday, July 11th. The shares were sold at an average price of $27.48, for a total transaction of $2,532,501.84. Following the completion of the transaction, the chief financial officer now directly owns 235,421 shares of the company’s stock, valued at approximately $6,469,369.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 236,489 shares of company stock valued at $6,440,888. 0.74% of the stock is currently owned by insiders.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.